Economic Evaluations of New Vaccine Introduction in Middle-Income Countries in the Middle East and North Africa Region: A Systematic Review
Vaccines · 02.07.2026 · 14 (7) · 591
DOI: 10.3390/vaccines14070591 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Vaccines, online erschienen am 02.07.2026. Verfasst von Chrissy Bishop und 7 weiteren Autor:innen. Beteiligte Einrichtung: Triangulate Health Ltd., Doncaster DN11 9QU, UK. Die Arbeit nennt 69 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Gavi, The Vaccine Alliance, UNICEF Regional Office for the Middle East and North Africa, Triangulate Health Ltd..
Abstract (Originalsprache)
Background/Objectives: Middle-income countries (MICs) in the Middle East and North Africa (MENA) face financial and health system barriers when introducing new vaccines. The Gavi MICs approach has supported the introduction of pneumococcal conjugate (PCV), human papillomavirus (HPV), and rotavirus (RV) vaccines; however, economic evidence from the region remains limited. This systematic review assessed the quantity, characteristics, and quality of economic evaluations of these vaccines in MENA MICs published between 2015 and 2025 and synthesised economic evidence to inform policy decisions in Algeria, Egypt, Iran, Jordan, Lebanon, Morocco, Palestine, and Tunisia.
Methods
Relevant databases and registries were searched for cost–effectiveness, cost–utility, cost–benefit, and budget impact analyses of PCV, HPV, and RV vaccination strategies. Two reviewers independently screened studies, extracted data, and assessed methodological quality.
Results
Twenty-six studies met the inclusion criteria, including 12 on HPV, nine on RV, and five on PCV. Vaccine introduction was the most commonly evaluated intervention (n = 23), and most studies were cost–effectiveness or cost–utility analyses adopting payer, health system, societal, or mixed perspectives. PCV and RV introduction were consistently found to be cost-effective or cost-saving. HPV introduction showed mixed results, particularly in Iran, but was generally cost-effective in Tunisia and Morocco. Reporting of vaccine coverage, delivery costs, and programmatic constraints was limited, and overall methodological quality varied.
Conclusions
Available evidence supports the economic value of PCV and RV introduction in MENA MICs, while HPV’s cost-effectiveness is context dependent. Future evaluations should incorporate dynamic modelling, implementation costs, and affordability considerations to better inform sustainable vaccine introduction.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Triangulate Health Ltd., Doncaster DN11 9QU, UK.
- UNICEF MENA Regional Office, Abdulqader Al-Abed Street, Building No. 15 Tla'a Al-Ali, Amman 11821, Jordan.
- UNICEF Headquarters, 3 UN Plaza, Room 816, New York, NY 10017, USA.
ORCID-Profile: Saadia Farrukh
Förderung
- Gavi, The Vaccine Alliance
- UNICEF Regional Office for the Middle East and North Africa
- Triangulate Health Ltd.
Zitieren
APA
Bishop, C., Politopoulou, K., Bermudez, M., Rodriguez-Cairoli, F., Abeshu, M., Kadandale, S., Oyatoye, I., & Farrukh, S. (2026). Economic Evaluations of New Vaccine Introduction in Middle-Income Countries in the Middle East and North Africa Region: A Systematic Review. Vaccines, 14(7), 591. https://doi.org/10.3390/vaccines14070591
Vancouver
Bishop C, Politopoulou K, Bermudez M, Rodriguez-Cairoli F, Abeshu M, Kadandale S, et al. Economic Evaluations of New Vaccine Introduction in Middle-Income Countries in the Middle East and North Africa Region: A Systematic Review. Vaccines. 2026;14(7):591. doi:10.3390/vaccines14070591
BibTeX
@article{Bishop2026,
author = {Bishop, Chrissy and Politopoulou, Konstantina and Bermudez, Maria and Rodriguez-Cairoli, Federico and Abeshu, Motuma and Kadandale, Sowmya and Oyatoye, Ibironke and Farrukh, Saadia},
title = {Economic Evaluations of New Vaccine Introduction in Middle-Income Countries in the Middle East and North Africa Region: A Systematic Review},
journal = {Vaccines},
year = {2026},
volume = {14},
number = {7},
pages = {591},
doi = {10.3390/vaccines14070591}
}
EUVIMED